Department of Research Impact and Outcome, Lovely Professional University, Punjab, 144411, India.
Endocr Metab Immune Disord Drug Targets. 2024;24(4):402-417. doi: 10.2174/1871530323666230825140808.
Obesity is a chronic lifestyle issue with devastating results. Behavioral changes are one of the initial lines of management strategies for obesity, but they are not very efficient management strategies. Many people also use surgical intervention to maintain a healthy weight, now considered to be the most common and effective obesity management. Chemically synthesized medicines fill the gap between lifestyle interventions and minimally invasive surgical management of obesity. The most common issue associated with monotherapy without side effects is its moderate effectiveness and higher dose requirement. Combination therapy is already used for many serious and complicated disease treatments and management and has shown efficacy as well. Generally, we use two or more medicines with different mechanisms of action for a better effect. The commonly used combination therapy for obesity management includes low-dose phentermine and prolonged and slow-releasing mechanism topiramate; naltrexone, and bupropion. Phentermine with inhibitors of Na-glucose cotransporter-2 or glucagon-like peptide-1 (GLP-1) agonists with gastric hormone or Na-glucose cotransporter-2 are two more viable combo therapy. This combination strategy aims to achieve success in bariatric surgery and the scientific community is working in this direction.
肥胖是一种慢性生活方式问题，会带来毁灭性的后果。行为改变是肥胖管理策略的初始方案之一，但它们并不是非常有效的管理策略。许多人还采用手术干预来维持健康体重，现在这种方法被认为是最常见和最有效的肥胖管理方法。化学合成药物填补了生活方式干预和肥胖微创管理之间的空白。单一药物治疗没有副作用，但最常见的问题是其效果中等，需要较高的剂量。联合治疗已经用于许多严重和复杂疾病的治疗和管理，并且已经显示出疗效。一般来说，我们使用两种或更多种具有不同作用机制的药物来获得更好的效果。肥胖管理中常用的联合治疗包括低剂量的苯丁胺和延长及缓慢释放机制的托吡酯；纳曲酮和安非他酮。苯丁胺与钠-葡萄糖共转运蛋白-2抑制剂或胰高血糖素样肽-1（GLP-1）激动剂与胃激素或钠-葡萄糖共转运蛋白-2联合使用是两种更可行的联合治疗方案。这种联合策略旨在实现减肥手术的成功，科学界正在朝着这个方向努力。
